Did anyone ask about the allegations in the conference call?
I predict this: no buyout. I don't think there would have been this dilution if buyout was in the works. So, $12? I doubt it.
We obviously still have some chance for FDA approval
The new reality is a biotech rundown. New Rule: The shorts will be given an opportunity to cover.